Animal experimental study demonstrates improved hemostatic efficacy but lower circulation of cold-stored platelets in immunodeficient mice, highlighting storage trade-offs.
Preclinical evaluation of novel platelet products requires an animal model that supports large-volume human platelet transfusion and achieves a high proportion of circulating human platelets. We developed a novel immunodeficient mouse model with repeated blood withdrawal and large-volume transfusion of human platelet concentrates suspended in platelet additive solution (PAS-PCs). The mice tolerated cumulative blood withdrawal of approximately 50 mL/kg and human PAS-PC transfusion volumes exceeding 50 mL/kg. We compared cold-stored and room temperature (RT)-stored PAS-PCs after 3–5, 7–9, and 10–14 days of storage in 60 mice (10 mice per group). In same-duration comparisons, hemostasis times were significantly shorter with cold-stored platelets than with RT-stored platelets after 3–5 days ( P = 0.034) and 10–14 days ( P = 0.003) of storage, with no significant difference after 7–9 days ( P = 0.437). In contrast, circulating human platelet concentrations after transfusion were lower with cold-stored platelets after 3–5 days ( P = 0.007) and 7–9 days ( P = 0.001) of storage. This model enables large-volume human platelet transfusion while simultaneously evaluating hemostatic efficacy and circulating human platelet concentrations in the same mice.
No takes yet. Share an insight, caveat, or question.
Uchiyama et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: